Patent · US Active

Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens

US9028840B2 · kind B2 · utility

2Cited by

4References

8Claims

0Family size

Assignees

Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE
Deutsches Krebsforschungszentrum · DE

Inventors

Dinesh Adhikary · Schwanau, DE
Uta Behrends · Munich, DE
Josef Mautner · Munich, DE
Henri-Jacques Delecluse · Heidelberg, DE
Regina Feederle · Munich, DE

Key dates

Filing date	Nov 27, 2008
Grant date	May 12, 2015
Priority date	—
Expiry date	Aug 14, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16234
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.